Cargando…
Early stopping of clinical trials
Early stopping of clinical trials in favour of a new treatment creates ethical and scientific difficulties, which are different from those associated with early stopping due to toxicity or futility. Two major breast cancer trials have recently taken such a decision, and the problem is relevant for s...
Autores principales: | Cuzick, Jack, Howell, Anthony, Forbes, John |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1242138/ https://www.ncbi.nlm.nih.gov/pubmed/16168134 http://dx.doi.org/10.1186/bcr1280 |
Ejemplares similares
-
Accountability in clinical trial diversity: The buck stops where?
por: Nephew, Lauren D.
Publicado: (2021) -
Outcome measures in clinical trials of treatments for acute severe haemorrhage
por: Brenner, Amy, et al.
Publicado: (2018) -
Early start and stop of biologics: has the time come?
por: van Vollenhoven, Ronald F, et al.
Publicado: (2014) -
Bone versus breast density
por: Cuzick, Jack
Publicado: (2006) -
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)